Hudson Way Capital Management LLC Sells 24,136 Shares of Axon Enterprise, Inc $AXON

Hudson Way Capital Management LLC trimmed its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 42.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,108 shares of the biotechnology company’s stock after selling 24,136 shares during the period. Axon Enterprise accounts for about 2.5% of Hudson Way Capital Management LLC’s investment portfolio, making the stock its 14th largest position. Hudson Way Capital Management LLC’s holdings in Axon Enterprise were worth $27,411,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. ICONIQ Capital LLC bought a new position in shares of Axon Enterprise in the second quarter valued at approximately $378,000. IHT Wealth Management LLC grew its stake in Axon Enterprise by 4.5% in the 2nd quarter. IHT Wealth Management LLC now owns 2,642 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 113 shares during the last quarter. George Kaiser Family Foundation raised its holdings in Axon Enterprise by 37.4% in the 2nd quarter. George Kaiser Family Foundation now owns 823 shares of the biotechnology company’s stock worth $681,000 after acquiring an additional 224 shares during the period. EP Wealth Advisors LLC lifted its position in Axon Enterprise by 14.0% during the 2nd quarter. EP Wealth Advisors LLC now owns 579 shares of the biotechnology company’s stock worth $479,000 after acquiring an additional 71 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its position in Axon Enterprise by 108.2% during the 2nd quarter. Engineers Gate Manager LP now owns 14,070 shares of the biotechnology company’s stock worth $11,649,000 after acquiring an additional 7,311 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of AXON stock opened at $564.28 on Friday. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The company has a market capitalization of $44.53 billion, a P/E ratio of 178.57, a P/E/G ratio of 133.45 and a beta of 1.40. The stock has a 50 day moving average of $623.94 and a two-hundred day moving average of $714.38. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The business’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 earnings per share. As a group, equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on AXON shares. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. The Goldman Sachs Group decreased their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Piper Sandler dropped their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $815.00.

Insider Buying and Selling

In related news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the sale, the president owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey C. Kunins sold 1,797 shares of the stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the transaction, the insider directly owned 83,485 shares of the company’s stock, valued at $45,017,616.55. This trade represents a 2.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 65,353 shares of company stock worth $39,252,286. Insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.